Evaluation of Adrenal Tumors and Analysis of the Metabolic Profile of Patients with Incidentaloma

Overview

Journal Rev Col Bras Cir

Date 2025 Jan 22

PMID 39841720

Authors

Pedro Victor Goncalves Montalvao

Iuri Moura Mangueira

Gabriel DA Motta Alves

Joao Vitor Fazzio Cordeiro

Marcia Helena Soares Costa

Guilherme DE Andrade Gagheggi Ravanini

Affiliations

Soon will be listed here.

Abstract

Introduction: Advances in imaging methods have led to an increasingly frequent diagnosis of adrenal gland lesions as incidental findings. Despite progress in this field, there is still limited information regarding the epidemiology of the clinical and metabolic profile of patients with adrenal incidentaloma (AI). The objective is analyze the epidemiology of adrenal tumors at Gaffrée e Guinle University Hospital (HUGG) and compare it with data from the literature.

Method: This is a cross-sectional study that included patients of any gender and age who was treated at HUGG for adrenal tumors.

Results: The following variables were evaluated: age, gender, functionality, benignity, and size. We also analyzed the metabolic profile of patients with AI, specifically those with mild autonomy cortisol secretion. Out of 31 patients with adrenal tumors, 68% were female. The mean age was 55 years with a standard deviation of ±16.2. 54% of the sample had adrenal incidentalomas. 93.6% of the sample had benign cases. Among the adrenal incidentalomas, 53% were non-functioning. In patients with adrenal tumors, only 10% had metabolic syndrome, while in patients with mild autonomous cortisol secretion, this number rose to 17%.

Conclusion: The sample of patients with adrenal tumors and incidentaloma at HUGG presented a prevalence of metabolic complications similar to that found in the literature.

References

Akaza I, Yoshimoto T, Iwashima F, Nakayama C, Doi M, Izumiyama H . Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment. Hypertens Res. 2011; 34(10):1111-5. DOI: 10.1038/hr.2011.90. View

Toniato A, Merante-Boschin I, Opocher G, Pelizzo M, Schiavi F, Ballotta E . Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009; 249(3):388-91. DOI: 10.1097/SLA.0b013e31819a47d2. View

Zografos G, Perysinakis I, Vassilatou E . Subclinical Cushing's syndrome: current concepts and trends. Hormones (Athens). 2014; 13(3):323-37. DOI: 10.14310/horm.2002.1506. View

Barzon L, Sonino N, Fallo F, Palu G, Boscaro M . Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149(4):273-85. DOI: 10.1530/eje.0.1490273. View

Guerrero M, Schreinemakers J, Vriens M, Suh I, Hwang J, Shen W . Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009; 209(6):727-32. DOI: 10.1016/j.jamcollsurg.2009.09.022. View

Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G . AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011; 164(6):851-70. DOI: 10.1530/EJE-10-1147. View

Cawood T, Hunt P, OShea D, Cole D, Soule S . Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009; 161(4):513-27. DOI: 10.1530/EJE-09-0234. View

Ng L, Libertino J . Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2002; 169(1):5-11. DOI: 10.1016/S0022-5347(05)64023-2. View

. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2001; 894:i-xii, 1-253. View

10.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

11.

Valli N, Catargi B, Ronci N, Vergnot V, Leccia F, Ferriere J . Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol. 2001; 144(4):401-8. DOI: 10.1530/eje.0.1440401. View

12.

Aron D, Terzolo M, Cawood T . Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012; 26(1):69-82. DOI: 10.1016/j.beem.2011.06.012. View

13.

Palmieri S, Morelli V, Polledri E, Fustinoni S, Mercadante R, Olgiati L . The role of salivary cortisol measured by liquid chromatography-tandem mass spectrometry in the diagnosis of subclinical hypercortisolism. Eur J Endocrinol. 2012; 168(3):289-96. DOI: 10.1530/EJE-12-0803. View

14.

Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C . Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study. Endocrine. 2020; 71(1):178-188. PMC: 7835305. DOI: 10.1007/s12020-020-02476-1. View

15.

Tsentidis C, Bampilis A, Ntova V, Fragkos D, Panos C, Limniati C . Metabolic Syndrome as a Predictor of Adrenal Functional Status: A Discriminant Multivariate Analysis Versus Logistic Regression Analysis. Horm Metab Res. 2018; 51(1):47-53. DOI: 10.1055/a-0754-6464. View

16.

Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A . Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175(2):G1-G34. DOI: 10.1530/EJE-16-0467. View

17.

Faludi A, Izar M, Kerr Saraiva J, Chacra A, Bianco H, Afiune Neto A . . Arq Bras Cardiol. 2017; 109(2 Supl 1):1-76. DOI: 10.5935/abc.20170121. View

18.

Kapoor A, Morris T, Rebello R . Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J. 2011; 5(4):241-7. PMC: 3147036. DOI: 10.5489/cuaj.11135. View

19.

Grumbach M, Biller B, Braunstein G, Campbell K, Carney J, Godley P . Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003; 138(5):424-9. DOI: 10.7326/0003-4819-138-5-200303040-00013. View

20.

Mayo-Smith W, Song J, Boland G, Francis I, Israel G, Mazzaglia P . Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017; 14(8):1038-1044. DOI: 10.1016/j.jacr.2017.05.001. View